Edition:
India

PAION AG (PA8G.DE)

PA8G.DE on Xetra

2.44EUR
23 Feb 2018
Change (% chg)

€-0.08 (-2.98%)
Prev Close
€2.52
Open
€2.49
Day's High
€2.53
Day's Low
€2.41
Volume
40,744
Avg. Vol
121,333
52-wk High
€3.53
52-wk Low
€2.15

Select another date:

Mon, Dec 18 2017

BRIEF-PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan

* SAID ON SUNDAY GRANTED EXCLUSIVE LICENSE TO MUNDIPHARMA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN JAPAN

BRIEF-PAION announces clinical development progress with remimazolam

* DGAP-NEWS: PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER HANA PHARM IN SOUTH KOREA

BRIEF-PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient

* ‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT

BRIEF-PAION ‍9-mth net loss at 8.5 mln euros

* DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2017

BRIEF-Paion: Japan patent office grants dosing patent for remimazolam

* DGAP-NEWS: PAION AG: JAPAN PATENT OFFICE GRANTS DOSING PATENT FOR REMIMAZOLAM IN JAPAN

BRIEF-PAION granted formulation patent for remimazolam in the EU

* DGAP-NEWS: PAION AG: EUROPEAN PATENT OFFICE GRANTS FORMULATION PATENT FOR REMIMAZOLAM IN THE EU

Select another date: